Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vvax001 in (Pre) Malignant Cervical Lesions
NCT03141463Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Vvax001 in cervical intraepithelial neoplasia (CIN) and Cervical Cancer (CC), sponsored by University Medical Center Groningen. Primary endpoint: Immunogenicity. Started Jan 2017; status: completed.
02
Drugs
Vvax001
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03141463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141463.